FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection By Ogkologos - October 2, 2025 293 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study MK-3475A-D77 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with... July 1, 2025 Abiraterone Acetate Plus Prednisone and LHRH Analogue is Active and Safe... October 4, 2021 Mutational Patterns Drive Metastatic Aggressiveness of Appendiceal Adenocarcinomas December 21, 2022 EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim September 18, 2025 Load more HOT NEWS Our sun safety messaging tours the UK with the NIVEA Sun... A Polygenic Risk Score Assessment Reveals More Screening Participants with Clinically... Immunotherapy Combinations for Treating Metastatic Melanoma and Using Technology to Find... ESMO Publishes First-Ever Guidance on Validation Requirements for AI-Based Biomarkers in...
